These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7201393)

  • 21. Immunity and tumors of the nervous system.
    Brooks WH; Netsky MG; Levine JE
    Surg Neurol; 1975 Apr; 3(4):184-6. PubMed ID: 1145415
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunogenetic control of brain tumor growth in rats.
    Albright AL; Gill TJ; Geyer SJ
    Cancer Res; 1977 Aug; 37(8 Pt 1):2512-21. PubMed ID: 889589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.
    Glick RP; Lichtor T; de Zoeten E; Deshmukh P; Cohen EP
    Neurosurgery; 1999 Oct; 45(4):867-74. PubMed ID: 10515482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-mediated immune response in rats immunized with chemically modified syngeneic glioma cells. Monitoring by in vivo parameters and in vitro immune cytolysis.
    Bilzer T; Stavrou D; Dahme E; Anzil AP
    Anticancer Res; 1982; 2(6):345-54. PubMed ID: 6984814
    [No Abstract]   [Full Text] [Related]  

  • 25. lacZ-neoR transfected glioma cells in syngeneic rats: growth pattern and characterization of the host immune response against cells transplanted inside and outside the CNS.
    Visted T; Thorsen J; Thorsen F; Read TA; Ulvestad E; Engebraaten O; Sorensen D; Ylä-Herttuala S; Tyynela K; Rucklidge G; Edvardsen K; Bjerkvig R; Lund-Johansen M
    Int J Cancer; 2000 Jan; 85(2):228-35. PubMed ID: 10629082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of various chemicals on the surface structure and the antigenicity of syngeneic glioma cells.
    Zänker KS; Stavrou D; Hultén M; Bilzer T
    Anticancer Res; 1981; 1(2):101-7. PubMed ID: 7347153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
    Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
    Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Active immunotherapy of cerebral tumor. 20 cases].
    Trouillas P; Lapras C
    Neurochirurgie; 1970; 16(2):143-70. PubMed ID: 4317954
    [No Abstract]   [Full Text] [Related]  

  • 29. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.
    Akasaki Y; Kikuchi T; Homma S; Abe T; Kofe D; Ohno T
    J Immunother; 2001; 24(2):106-13. PubMed ID: 11265767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma.
    Smith KE; Janelidze S; Visse E; Badn W; Salford L; Siesjö P; Darabi A
    Int J Cancer; 2007 Jan; 120(1):75-80. PubMed ID: 17044023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Glial tumor cell proliferation and immune response in the brain].
    Yamasaki T; Akiyama Y; Fukuda M; Kimura Y; Moritake K; Enomoto K; Maeno T
    Hum Cell; 1995 Sep; 8(3):99-106. PubMed ID: 8652453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment.
    Cantini G; Pisati F; Mastropietro A; Frattini V; Iwakura Y; Finocchiaro G; Pellegatta S
    Cancer Immunol Immunother; 2011 Dec; 60(12):1739-50. PubMed ID: 21779877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
    Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
    Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential usefulness of a cultured glioma cell line induced by Rous sarcoma virus in B10.A mouse as an immunotherapy model.
    Sakamoto K; Hoshino H; Kiuchi Y; Nakano G; Nagamachi Y
    Jpn J Exp Med; 1989 Oct; 59(5):173-80. PubMed ID: 2559217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts.
    Siesjö P; Visse E; Lindvall M; Salford L; Sjögren HO
    Cancer Immunol Immunother; 1993 Jul; 37(1):67-74. PubMed ID: 8513454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioma immunotherapy with combined autologous tumor cell and endothelial cell vaccine in vivo.
    Sakamoto N; Uemae Y; Ishikawa E; Takano S; Nakai K; Yamamoto T; Zaboronok A; Matsumura A
    Neurol Med Chir (Tokyo); 2012; 52(4):194-201. PubMed ID: 22522329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma.
    Yi L; Xiao H; Xu M; Ye X; Hu J; Li F; Li M; Luo C; Yu S; Bian X; Feng H
    J Neuroimmunol; 2011 Mar; 232(1-2):75-82. PubMed ID: 21056915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection.
    Segal BM; Glass DD; Shevach EM
    J Immunol; 2002 Jan; 168(1):1-4. PubMed ID: 11751938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation of membrane fractions with enhanced tumor-transplantation-antigen activity from tumor cells infected with influenza virus.
    Boone CW; Orme TW; Blackman K; Gillette R
    J Natl Cancer Inst; 1973 Oct; 51(4):1141-4. PubMed ID: 4355600
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cloning of mouse glioma-specific killer T cells].
    Yamasaki T; Yamashita J; Handa H; Namba Y; Hanaoka M
    Neurol Med Chir (Tokyo); 1983 Mar; 23(3):181-3. PubMed ID: 6193442
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.